.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Recent clinical evidence suggests a transformative role for CKM therapy in T1D and chronic kidney disease (CKD). Patients with Type 1 diabetes often face high risks of renal and cardiovascular complications. Consequently, researchers investigated the off-label use of GLP-1RA and SGLT2i therapies in this population. A large-scale analysis of US database records from 2016 to 2023 provides new insights. Interestingly, more than 10% of adults with T1D and CKD were already utilizing these therapies. The primary focus was the impact on the urinary albumin-to-creatinine ratio (UACR). Notably, patients on CKM therapy experienced a 30% reduction in UACR faster than controls (HR 0.76).
Safety remains a paramount concern for clinicians. Specifically, the risk of diabetic ketoacidosis (DKA) has historically limited SGLT2i use in T1D. However, this study found no increase in DKA or hypoglycemia rates among users. Therefore, these findings support the potential for integrating CKM therapies into T1D management. Furthermore, the reduction in albuminuria suggests a strong renal-protective effect. Clinicians must still follow local guidelines when prescribing these agents and monitor patients closely for metabolic changes.
In this study, CKM therapy (SGLT2i and GLP-1RA) did not increase the risk of diabetic ketoacidosis or hypoglycemia. However, patients should still be monitored closely due to historical risks associated with these drug classes in T1D.
Reducing the urinary albumin-to-creatinine ratio (UACR) is a clinical marker of improved kidney health. It often correlates with a slower progression toward end-stage renal disease (ESRD).
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Refer to the latest local and national guidelines for clinical practice.
References
Caramori ML et al. Cardio-Kidney-Metabolic Therapy Use Among Adults With Type 1 Diabetes and Chronic Kidney Disease. Diabetes Obes Metab. 2026 Mar 12. doi: 10.1111/dom.70640. PMID: 41816887.
American Diabetes Association. Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl. 1):S1-S321.
KDIGO 2024 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International. 2024;105(4S):S1-S103.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A large US database study shows CKM therapy in T1D and CKD is associated with UACR reduction and safe use regarding DKA and hypoglycemia....
4 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
